In Vivo Imaging Reagents

CD BioSciences, a US-based biotechnology company focusing on the development of imaging technology, has announced the launch of its new range of In Vivo Imaging Reagents, including fluorescent imaging probes, fluorescent labeling dyes, fluorescent imaging panels, and fluorescent nanoparticles, designed to provide researchers with a non-invasive approach to visualize and quantify cellular and biological functions in living systems. In vivo fluorescence imaging is a non-invasive method for visualizing and quantifying cellular and biological functions. Using these biospecific, validated fluorescent probes, dyes and panels, scientists can visualize disease pathogenesis and related biological processes in living systems. In certain preclinical studies, fluorescence can reveal disease processes and therapeutic effects earlier and more powerfully, making it an attractive alternative to standard imaging methods. There are many advantages to using in vivo fluorescence imaging for scientific research. CD BioSciences now provides customers with fluorescent imaging probes, fluorescent label dyes, fluorescent imaging plates and fluorescent nanoparticles for scientific research. In addition, the company offers bioluminescent substrates and lentiviral particles, bioluminescent tumor cell lines, bioluminescent bacterial strains, and microbubble contrast agents. The company’s commitment to innovation and quality is evident in the development of these reagents, which are expected to revolutionize the field of in vivo imaging. For example, the Pan Cathepsin Fluorescent Probe (Catalog NO: VIR030106) can be used for imaging various disease-related events. Proteases play an important role in protein regulation. Lysosomal proteases are a class of proteases whose altered activity predicts many disease-related processes such as cancer, inflammation, arthritis, and cardiovascular disease.